

Title – Co11ab and BioMedtech ecosystem in Singapore



Biography – Dr Ervinna PANG, Director

Dr Pang is the Director of co11ab and a seasoned Bioentrepreneur. She played crucial role in building multiple Biotech and Medtech startups focused on cell and gene therapy, and in vitro diagnostics. Notable companies currently in clinical stage include Lion TCR, SCG Cell Therapy, BioSyngen, and BioCheetah.

With a PhD from the Max Planck Institute for Infection Biology, Dr Pang joined Bayer Pharmaceuticals and contributed to External Innovation in the Asia Pacific region, from target discovery to Phase I clinical trials. Her multidisciplinary scientific background in oncology, immunology, and infection biology led her to take on a second role at Bayer in Germany, where she contributed to the clinical development of one of the company's earliest immune-oncology assets. Dr Pang's experience expanded with her involvement in Boehringer Ingelheim, managing External Innovation and Business Development in Shanghai, focusing on partnerships and potential venture investments in Greater China.

Dr Pang plays an active role in the innovation and entrepreneurship ecosystem. During her tenure at A*STAR, she actively participated in intellectual property (IP) management, licensing, and fundraising for portfolio companies. As a founding team of co11ab, she continues to drive innovation, entrepreneurship, impact, and value creation.

Dr Pang, a Chartered Valuer and Appraiser (CVA) since 2021, specializes in valuing intangible assets, particularly IP rights that contribute to Enterprise Value. She holds executive program certifications from the Wharton School of the University of Pennsylvania, and multiple IP certifications from WIPO. Dr Pang is also a member of the Singapore Institute of Directors.